Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Molycorp Inc (MCP): Here’s What You Have To See

On an adjusted basis, Molycorp Inc (NYSE:MCP) crushed analyst expectations, beating on both earnings and revenues. Despite favorable comments from the company regarding the duration of 2013, analysts have maintained a grim view of the stock for the rest of the year. This didn’t prevent the stock from surging nearly 25% in after-hours trading – although this push pulled back a bit, seeing shares trade up about 17% during Friday morning trading. The question for investors now is where do shares actually go given the sharp disconnection between the company’s message and that of analysts.

Molycorp Inc (NYSE:MCP)

By the numbers
Molycorp Inc (NYSE:MCP) reported adjusted EPS of $0.15 on revenues of $146.4 million. While this represents an EPS slide from the $0.07 achieved a year ago, revenues rose and both EPS and revenues were significantly above consensus estimates. Analysts had been expecting a loss of $0.31 per share on revenues of $135.6 million. Shares have been under constant pressure since the Rare Element Resources Ltd (NYSEMKT:REE)-earth element sector came under pressure, so any positive news can serve as a major catalyst.

In the earnings call, President and CEO Constantine Karayannopoulos gave a positive outlook:

We are however beginning to see signs of demand returning to more normal levels across several segments. Customers appear to be working down inventories that were built up in 2011 and 2012 and we are starting to return to more normal purchasing patterns. Our production ramp up of Mountain Pass is progressing well.

The statement contains several critical factors for Molycorp Inc (NYSE:MCP), and the entire industry, for which Molycorp Inc (NYSE:MCP) has become the standard-bearer. Specific to the company, progress at the Mountain Pass location is a critical step as it represents one of the few significant operations outside of China.

The broader comments are a boon for the industry, explaining why competitors like Avalon Rare Metals Inc (US listing)(NYSEMKT:AVL) traded up nearly 10% and Rare Earth Elements surged over 12% on the news. If industrial demand for rare-earth elements is stabilizing and beginning to build, then all three of these companies will benefit. High inventories in the hands of customers have been a major drag on prices for an extended period, and If this trend is reversing, Molycorp Inc (NYSE:MCP) should see continuing strength in the later part of the year.

Looking ahead
It will be instructive to see if the better-than-expected report and positive commentary will alter expectations for the rest of the year. Analysts have been hard on the industry, which has seen huge losses for most shares after rare-earth metal prices cratered. The original explosion in rare-earth elements was a reaction to China, the primary controller of these materials, tightening export laws and greatly squeezing supply. As that issue played out, prices fell.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.